Showing results (61-70 of 88) with videos related to

Sort By:
Pageof 9
Multiple Sclerosis and Related Disorders|January 10, 2019
Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort studyAi-Lan Nguyen, Eva Kubala Havrdova, Dana Horakova, et al.
Therapeutic Advances in Neurological Disorders|November 11, 2024
The impact of COVID-19 infection on multiple sclerosis disease course across 12 countries: a propensity-score-matched cohort studyDavid Levitz, Yi Chao Foong, Paul Sanfilippo, et al.
European Journal of Immunology|October 6, 2023
Single-cell multi-omics analysis of COVID-19 patients with pre-existing autoimmune diseases shows aberrant immune responses to infectionAnis Barmada, Louis-François Handfield, Gerard Godoy-Tena, et al.
Journal of Clinical Medicine|December 9, 2023
Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies: A Multi-Centre StudyAgustín Sancho-Saldaña, Anna Gil-Sánchez, Cristina González-Mingot, et al.
Brain : a Journal of Neurology|July 13, 2016
Defining secondary progressive multiple sclerosisJohannes Lorscheider, Katherine Buzzard, Vilija Jokubaitis, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 15, 2019
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosisTomas Kalincik, Eva Kubala Havrdova, Dana Horakova, et al.
Brain : a Journal of Neurology|October 21, 2017
Towards personalized therapy for multiple sclerosis: prediction of individual treatment responseTomas Kalincik, Ali Manouchehrinia, Lukas Sobisek, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 1, 2024
Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosisIzanne Roos, Sifat Sharmin, Charles Malpas, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 5, 2016
Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosisChunrong Tao, Steve Simpson, Ingrid van der Mei, et al.
The Lancet. Neurology|February 18, 2017
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort studyTomas Kalincik, J William L Brown, Neil Robertson, et al.
Pageof 9